$SAGE
Sage Therapeutics, Inc.

2020 Q4 Form 10-K Financial Statement

#000156459021007819 Filed on February 24, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $1.109B $1.639M $1.089M
YoY Change 56491.12% -54.09% 24.74%
Cost Of Revenue $100.0K $100.0K $100.0K
YoY Change -50.0% 0.0% 127.27%
Gross Profit $1.109B $1.500M $1.000M
YoY Change 65141.18% -55.88% 20.63%
Gross Profit Margin 99.99% 91.52% 91.83%
Selling, General & Admin $53.50M $35.10M $38.22M
YoY Change -37.13% -60.34% -56.68%
% of Gross Profit 4.82% 2340.0% 3822.4%
Research & Development $81.70M $74.10M $73.32M
YoY Change -10.51% -27.43% -17.67%
% of Gross Profit 7.37% 4940.0% 7332.0%
Depreciation & Amortization $600.0K $700.0K $700.0K
YoY Change -14.29% 0.0% 40.0%
% of Gross Profit 0.05% 46.67% 70.0%
Operating Expenses $135.2M $108.8M $140.1M
YoY Change -23.44% -42.96% -21.02%
Operating Profit $974.0M -$107.2M -$139.0M
YoY Change -657.71% -42.75% -21.25%
Interest Expense $800.0K $1.300M $2.686M
YoY Change -86.44% -81.94% -67.32%
% of Operating Profit 0.08%
Other Income/Expense, Net $100.0K $100.0K -$66.00K
YoY Change 0.0% -512.5%
Pretax Income $974.9M -$105.7M -$136.3M
YoY Change -677.89% -41.28% -18.97%
Income Tax
% Of Pretax Income
Net Earnings $974.9M -$105.7M -$136.3M
YoY Change -678.05% -41.24% -18.95%
Net Earnings / Revenue 87.89% -6451.19% -12520.39%
Basic Earnings Per Share $18.71 -$2.03 -$2.63
Diluted Earnings Per Share $18.19 -$2.03 -$2.63
COMMON SHARES
Basic Shares Outstanding 51.98M 51.93M
Diluted Shares Outstanding 51.98M 51.93M

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.100B $670.9M $758.9M
YoY Change 108.21% -40.34% -38.63%
Cash & Equivalents $1.661B $186.6M $260.6M
Short-Term Investments $438.5M $484.3M $498.3M
Other Short-Term Assets $22.80M $30.30M $28.90M
YoY Change -14.61% -0.33% 7.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.122B $698.9M $785.4M
YoY Change 105.04% -39.37% -37.84%
LONG-TERM ASSETS
Property, Plant & Equipment $6.755M $7.404M $8.077M
YoY Change -25.98% -20.94% -3.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.341M $5.800M $5.800M
YoY Change -11.92% 51.91% 44.17%
Total Long-Term Assets $36.88M $39.70M $41.80M
YoY Change -24.83% -22.2% -19.58%
TOTAL ASSETS
Total Short-Term Assets $2.122B $698.9M $785.4M
Total Long-Term Assets $36.88M $39.70M $41.80M
Total Assets $2.159B $738.6M $827.2M
YoY Change 99.16% -38.64% -37.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.691M -$24.90M $2.400M
YoY Change -75.82% -593.95% -80.69%
Accrued Expenses $54.85M $46.76M $53.33M
YoY Change -36.67% -40.15% -9.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.20M $59.70M $64.30M
YoY Change -40.06% -34.36% -18.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $270.0K $21.40M $23.00M
YoY Change -47.98% 6194.12% 5509.76%
Total Long-Term Liabilities $270.0K $21.40M $23.00M
YoY Change -47.98% 6194.12% 5509.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.20M $59.70M $64.30M
Total Long-Term Liabilities $270.0K $21.40M $23.00M
Total Liabilities $86.91M $81.00M $87.30M
YoY Change -37.7% -33.96% -22.52%
SHAREHOLDERS EQUITY
Retained Earnings -$1.037B -$2.000B -$1.900B
YoY Change -36.88% 35.6% 46.15%
Common Stock $3.110B
YoY Change 20.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.072B $657.6M $739.9M
YoY Change
Total Liabilities & Shareholders Equity $2.159B $738.6M $827.2M
YoY Change 99.16% -38.64% -37.12%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income $974.9M -$105.7M -$136.3M
YoY Change -678.05% -41.24% -18.95%
Depreciation, Depletion And Amortization $600.0K $700.0K $700.0K
YoY Change -14.29% 0.0% 40.0%
Cash From Operating Activities $1.011B -$91.00M -$119.0M
YoY Change -966.32% -29.29% -10.79%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $45.50M $13.50M $177.5M
YoY Change -360.0% -93.56% -417.53%
Cash From Investing Activities $45.50M $13.50M $177.4M
YoY Change -352.78% -93.5% -405.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 419.7M 3.600M 300.0K
YoY Change 19885.71% -74.29% -98.04%
NET CHANGE
Cash From Operating Activities 1.011B -91.00M -119.0M
Cash From Investing Activities 45.50M 13.50M 177.4M
Cash From Financing Activities 419.7M 3.600M 300.0K
Net Change In Cash 1.476B -73.90M 58.70M
YoY Change -1213.27% -179.38% -133.31%
FREE CASH FLOW
Cash From Operating Activities $1.011B -$91.00M -$119.0M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow $1.011B -$91.00M -$119.0M
YoY Change -969.3% -28.18% -9.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 sage Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
CY2020Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2020 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
true
CY2020Q4 us-gaap Defined Contribution Plan Sponsor Location Extensible List
DefinedContributionPlanSponsorLocationExtensibleList
country:US
CY2019Q4 us-gaap Defined Contribution Plan Sponsor Location Extensible List
DefinedContributionPlanSponsorLocationExtensibleList
country:US
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M9D
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
215 First Street
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
126705000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
881688000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26700000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1035093000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9126000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2367000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25064000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33771000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3341000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3793000
CY2020Q4 us-gaap Assets
Assets
2159246000
CY2019Q4 us-gaap Assets
Assets
1084150000
CY2018Q4 us-gaap Defined Contribution Plan Sponsor Location Extensible List
DefinedContributionPlanSponsorLocationExtensibleList
country:US
CY2019Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2018Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-36544
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4486580
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2020 dei City Area Code
CityAreaCode
617
CY2020 dei Local Phone Number
LocalPhoneNumber
299-8380
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020Q2 dei Entity Public Float
EntityPublicFloat
2120561372
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58381933
CY2020 dei Security12b Title
Security12bTitle
common stock, $0.0001 par value per share
CY2020Q1 us-gaap Revenues
Revenues
2286000
CY2020Q2 us-gaap Revenues
Revenues
1089000
CY2020Q3 us-gaap Revenues
Revenues
1639000
CY2020Q4 us-gaap Revenues
Revenues
1109186000
CY2020 us-gaap Operating Expenses
OperatingExpenses
517974000
CY2019 us-gaap Operating Expenses
OperatingExpenses
714992000
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
27804000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
196952000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
596226000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-708124000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-393238000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
20334000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-486000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-680238000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1810000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-486000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9597000
CY2018 us-gaap Revenues
Revenues
90273000
CY2018 us-gaap Operating Expenses
OperatingExpenses
483511000
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.08
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46121194
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46121194
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
67204000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3691000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15266000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54851000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
86618000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8662000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10244000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-880000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-373368000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
112128000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19438000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26848000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
270000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
519000
CY2020Q4 us-gaap Liabilities
Liabilities
86912000
CY2019Q4 us-gaap Liabilities
Liabilities
139495000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58311444
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51880227
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58308411
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51877194
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3109807000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2587322000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1037494000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1643567000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
415000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1295000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2072334000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
944655000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2159246000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1084150000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
292714000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
345777000
CY2020 us-gaap Restructuring Charges
RestructuringCharges
27743000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
82000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.43
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.38
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50833837
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53003115
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11511000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-32157000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1810000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50833837
CY2020 us-gaap Net Income Loss
NetIncomeLoss
606073000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-372882000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1810000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
475475000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27014000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2705000
CY2018 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
98000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
100993000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
631154000
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-486000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-904000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-372882000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
862971000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44276000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5744000
CY2019 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
189000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
151508000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
560948000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-2175000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-680238000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
944655000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5082000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4936000
CY2020 sage Stock Issued During Period Value Stock Purchase Agreement
StockIssuedDuringPeriodValueStockPurchaseAgreement
417500000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-880000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
606073000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2072334000
CY2020 us-gaap Profit Loss
ProfitLoss
606073000
CY2019 us-gaap Profit Loss
ProfitLoss
-680238000
CY2018 us-gaap Profit Loss
ProfitLoss
-372882000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
95994000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
153231000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
101963000
CY2020 sage Premium On Marketable Securities
PremiumOnMarketableSecurities
1736000
CY2019 sage Premium On Marketable Securities
PremiumOnMarketableSecurities
3674000
CY2018 sage Premium On Marketable Securities
PremiumOnMarketableSecurities
215000
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1048000
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
6966000
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
9892000
CY2020 us-gaap Depreciation
Depreciation
2630000
CY2019 us-gaap Depreciation
Depreciation
2283000
CY2018 us-gaap Depreciation
Depreciation
1143000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3879000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4781000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15462000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-452000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3793000
CY2019 sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-8168000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
901749000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
458720000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
345000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
442684000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
193310000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
51000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
664280000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
9262000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2175000
CY2019 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
328000
CY2020 sage Proceeds From The Sale Of Common Stock Under The Stock Purchase Agreement
ProceedsFromTheSaleOfCommonStockUnderTheStockPurchaseAgreement
417500000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
631494000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
659358000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-113774000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
872000
CY2018 sage Noncash Or Part Noncash Landlord Tenant Incentive
NoncashOrPartNoncashLandlordTenantIncentive
229000
CY2020 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
606100000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1000000000.0
CY2020 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1000000000.0
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates<span style="font-style:normal;"> </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. <span style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including developments related to the scope and duration of the pandemic; </span><span style="color:#000000;">the duration and severity of precautionary measures taken to curb the spread of COVID-19, the length, location and frequency of surges or waves of COVID-19 cases and the timing and success of the roll-out of vaccines for COVID-19, and any return to normal business operations across the U.S</span><span style="Background-color:#FFFFFF;color:#212529;">. The Company has made estimates of the impact of the COVID-19 pandemic within its consolidated financial statements, and there may be changes to those estimates in future periods. </span>Actual results could differ from those estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and of Significant Suppliers</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains accounts for all cash and cash equivalents at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</p>
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1661082000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
438467000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2099549000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
126705000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
881688000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1008393000
CY2020Q4 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2019Q4 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
438052000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
451000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
438467000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
880393000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1449000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
154000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
881688000
CY2020Q4 sage Marketable Securities Held To Maturity Fair Value
MarketableSecuritiesHeldToMaturityFairValue
5100000
CY2019Q4 sage Marketable Securities Held To Maturity Fair Value
MarketableSecuritiesHeldToMaturityFairValue
137100000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
86618000
CY2020Q4 sage Accrued Restructuring Expenses
AccruedRestructuringExpenses
203000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22011000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
16720000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
947000
CY2020Q4 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P5Y
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5300000
CY2020 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-01-31
CY2020Q4 sage Remaining Amount Of Lease Write Off
RemainingAmountOfLeaseWriteOff
2300000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
700000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25064000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33771000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8662000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10244000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19438000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26848000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
28100000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
37092000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
8838000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
2285000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
2675000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
74000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
438000
CY2020 us-gaap Lease Cost
LeaseCost
11197000
CY2019 us-gaap Lease Cost
LeaseCost
12917000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
6500000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
9231000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
9946000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
872000
CY2020 sage Lease Asset De Recognized Upon Lease Cancellation
LeaseAssetDeRecognizedUponLeaseCancellation
2310000
CY2020Q4 sage Remaining Amount Of Lease Write Off
RemainingAmountOfLeaseWriteOff
2300000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2020 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2019 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
164.00
CY2018Q1 sage Proceeds From Issuance Of Common Stock Net Of Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfOfferingExpenses
631200000
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3833334
CY2019Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
150.00
CY2019Q1 sage Proceeds From Issuance Of Common Stock Net Of Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfOfferingExpenses
560900000
CY2020 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
3033
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12535574
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4420049
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
550890
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
101963000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
95994000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
101963000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
109.92
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
95994000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153231000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153231000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
37.53
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
82.39
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7786
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7134
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0097
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0221
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2020 sage Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageEstimatedForfeitureRate
0.206
CY2019 sage Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageEstimatedForfeitureRate
0.137
CY2020 us-gaap Net Income Loss
NetIncomeLoss
606073000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51983188
CY2020 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
1019927
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53003115
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.66
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.43
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7445
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0268
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
CY2018 sage Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageEstimatedForfeitureRate
0.107
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-680238000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-372882000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50833837
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46121194
CY2019 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2018 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50833837
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46121194
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.38
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.08
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.38
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.08
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4781737
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7710947
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6788318
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
639986000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.057
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.009
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-634289000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-296040000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-33913000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-45949000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-76842000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
606073000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-680238000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-372882000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.028
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.060
CY2020 sage Effective Income Tax Rate Reconciliation Premium On Equity Investment
EffectiveIncomeTaxRateReconciliationPremiumOnEquityInvestment
0.101
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.014
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.025
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.012
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.016
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.043
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.015
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.024
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.025
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.176
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.258
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.276
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.005
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.007
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
222607000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
348848000
CY2020Q4 sage Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
873000
CY2019Q4 sage Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
982000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
90460000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
80088000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
3157000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
4055000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1614000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
2002000
CY2020Q4 sage Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
56520000
CY2019Q4 sage Deferred Tax Assets Stock Options
DeferredTaxAssetsStockOptions
46750000
CY2020Q4 sage Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
-5981000
CY2019Q4 sage Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
-8059000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
6705000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
8852000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
148000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-246000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
376103000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
483272000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
376103000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
483272000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
41700000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
438400000
CY2020 sage Federal Net Operating Loss Carry Forwards Expiration Year
FederalNetOperatingLossCarryForwardsExpirationYear
2033
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2018 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
3600000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1800000
CY2020 sage State Net Operating Loss Carry Forwards Expiration Year
StateNetOperatingLossCarryForwardsExpirationYear
2033
CY2020Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
42300000
CY2020 sage Tax Credits Expiration Start Year
TaxCreditsExpirationStartYear
2034
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-107200000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
376100000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
483300000
CY2020 sage Valuation Allowance Deferred Tax Increase Decrease Amount
ValuationAllowanceDeferredTaxIncreaseDecreaseAmount
-107200000
CY2019 sage Valuation Allowance Deferred Tax Increase Decrease Amount
ValuationAllowanceDeferredTaxIncreaseDecreaseAmount
174900000
CY2018 sage Valuation Allowance Deferred Tax Increase Decrease Amount
ValuationAllowanceDeferredTaxIncreaseDecreaseAmount
102900000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2020 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2200000
CY2020Q2 sage Operating Expenses Workforce Reduction Percentage
OperatingExpensesWorkforceReductionPercentage
0.53
CY2020 us-gaap Restructuring Charges
RestructuringCharges
27743000
CY2020 us-gaap Payments For Restructuring
PaymentsForRestructuring
25102000
CY2020 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
2438000
CY2020Q4 us-gaap Restructuring Reserve
RestructuringReserve
203000
CY2020 us-gaap Revenues
Revenues
1114200000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
133910000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
140056000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
108797000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
135211000
CY2020 us-gaap Operating Expenses
OperatingExpenses
517974000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-131624000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-138967000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-107158000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
973975000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
596226000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-126740000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-136347000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-105735000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
974895000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
606073000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
18.71
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.66
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.44
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
18.19
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.43
CY2019Q1 us-gaap Revenues
Revenues
465000
CY2019Q2 us-gaap Revenues
Revenues
873000
CY2019Q3 us-gaap Revenues
Revenues
3570000
CY2019Q4 us-gaap Revenues
Revenues
1960000
CY2019 us-gaap Revenues
Revenues
6868000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
170317000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
177330000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
190747000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
176598000
CY2019 us-gaap Operating Expenses
OperatingExpenses
714992000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-169852000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-176457000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-187177000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-174638000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-708124000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-163406000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-168221000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-179958000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-168653000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-680238000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.37
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.28
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.48
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.25
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.38

Files In Submission

Name View Source Status
0001564590-21-007819-index-headers.html Edgar Link pending
0001564590-21-007819-index.html Edgar Link pending
0001564590-21-007819.txt Edgar Link pending
0001564590-21-007819-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g0hjmtqug45z000001.jpg Edgar Link pending
guju4jyz4mws000001.jpg Edgar Link pending
gyfd4wrk5srj000001.jpg Edgar Link pending
gyfd4wrk5srj000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-10k_20201231.htm Edgar Link pending
sage-10k_20201231_htm.xml Edgar Link completed
sage-20201231.xsd Edgar Link pending
sage-20201231_cal.xml Edgar Link unprocessable
sage-20201231_def.xml Edgar Link unprocessable
sage-20201231_lab.xml Edgar Link unprocessable
sage-20201231_pre.xml Edgar Link unprocessable
sage-ex1038_558.htm Edgar Link pending
sage-ex1039_559.htm Edgar Link pending
sage-ex1040_251.htm Edgar Link pending
sage-ex1041_252.htm Edgar Link pending
sage-ex1042_253.htm Edgar Link pending
sage-ex211_8.htm Edgar Link pending
sage-ex231_7.htm Edgar Link pending
sage-ex311_9.htm Edgar Link pending
sage-ex312_6.htm Edgar Link pending
sage-ex321_10.htm Edgar Link pending
Show.js Edgar Link pending